The analysis focused on dapagliflozin identified all four targets as associated with diabetes mellitus (SGLT1; SGLT6; SGLT2; SGLT3); while ertugliflozin and sergliflozin were regulating three of them (SGLT1; SGLT2; SGLT3). Here, SLC5A1 is linked to diabetes mellitus.